Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 49

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Myelin oligodendrocyte glycoprotein antibody-associated disease

Recruiting

Study of Early versus Delayed Treatment with Azathioprine or Rituximab in Children with Anti-MOG Antibody Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Dementia Alzheimer's type

Recruiting

Study on Donepezil Versus Non-drug Treatment for Patients with Alzheimer's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Donepezil
  • Sponsor:Assistance Publique Hopitaux De Paris

Glioblastoma

Recruiting

Study on Glioblastoma Treatment with Metformin, Temozolomide, and Radiotherapy for Newly Diagnosed Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Hospital Foch

Friedreich's ataxia

Recruiting

Long-term safety and effectiveness study of vatiquinone (oral capsules) in patients with Friedreich ataxia who have previously received this treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vatiquinone
  • Sponsor:PTC Therapeutics Inc.

Cerebral haemorrhage

Recruiting

Study on Avoiding Anticoagulation with Apixaban for Patients with Intracerebral Hemorrhage

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Centre Hospitalier Universitaire De Lille

Cerebral haemorrhage

Recruiting

Study on Anakinra for Patients with Intracerebral Hemorrhage to Reduce Brain Swelling After Stroke

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Stichting Radboud University Medical Center

Muscle spasticity

Recruiting

Study on the Safety and Effectiveness of IncobotulinumtoxinA for Treating Limb Spasticity in Children with Cerebral Palsy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Orthostatic hypotension

Recruiting

Study on the Effects of Fludrocortisone in Treating Neurogenic Orthostatic Hypotension in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fludrocortisone Acetate
  • Sponsor:H.A.C. Pharma

Ehlers-Danlos syndrome+4

Recruiting

Study on Valsartan for Slowing Aortic Root Dilatation in Children and Young Adults with Marfan Syndrome and Related Conditions

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Valsartan
  • Sponsor:Medical University Of Gdansk

Ocular myasthenia

Not yet recruiting

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Ocular myasthenia

Not yet recruiting

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Partial seizures

Not yet recruiting

A study to evaluate the effectiveness and safety of vormatrigine in adults with focal epilepsy who are taking one to three anti-seizure medications.

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:VORMATRIGINE
  • Sponsor:Praxis Precision Medicines Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.